Synergy Pharmaceuticals LLC
(Other OTC/NBB : SGYP)

( )
SGYP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -0.07%30.2414.1%$177.94m
HZNPHorizon Therapeutics Plc 0.00%91.455.5%$174.64m
GWPHGW Pharmaceuticals Plc 0.00%218.366.1%$132.57m
CTLTCatalent, Inc. 0.06%109.982.1%$128.58m
BHCBausch Health Cos., Inc. -0.07%30.240.0%$123.31m
ICLRICON plc 0.00%196.434.2%$121.81m
UTHRUnited Therapeutics Corp. 0.00%202.7814.1%$98.97m
JAZZJazz Pharmaceuticals Plc 0.00%166.372.3%$88.00m
SAVACassava Sciences, Inc. 0.00%35.670.0%$69.79m
ARGXargenx SE 0.00%272.780.0%$50.95m
SAGESAGE Therapeutics, Inc. 0.00%75.677.6%$37.98m
PRGOPerrigo Co. Plc 0.07%40.416.9%$37.14m
AMRNAmarin Corp. Plc 0.00%5.111.5%$28.81m
PCRXPacira Biosciences, Inc. 0.00%69.439.9%$26.96m
ICPTIntercept Pharmaceuticals, Inc. 0.00%21.4116.8%$21.61m

Company Profile

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.